Sacubitril, Valsartan, Circadian Rhythm, Melatonin, Experimental Arterial Hypertension


The circadian rhythm of blood pressure (BP) has been getting more attention since a rise in nocturnal BP and an increase in morning BP have been found to be independent risk factors for cardio-cerebrovascular disorders. The renin-angiotensin-aldosterone system (RAAS) is implicated in BP circadian rhythm, and RAAS inhibitors play an important role in BP circadian rhythm management.

Experiments were carried out on male rats weighing 200,0-250,0 g. Animals were randomly divided into the following groups: I – control group; II – DOCA-salt hypertensive group; III – S/V oral dose of 30 mg/kg per day after 28-day intake of DOCA and salt solutions administration. IV - sacubitril / valsartan (S/V) oral dose 30 mg/kg per day with DOCA and salt solutions as drinking water for 4 weeks;

In II group of rats with DOCA-salt arterial hypertension (AH) the mean values of systolic blood pressure (SBP) – 153,6 ± 5,4 mmHg, diastolic blood pressure DBP – 67,9 ± 2,8 mmHg and heart rate (HR) – 394 ± 12/min were significantly higher in comparison with control group of animals (123,0 ± 5,2 mmHg, P<0.001), (55,6 ± 3,0 mmHg, p<0.05) and (361 ± 24/min, p<0.001), respectively. As for III group of animals, treatment with the S/V combination proved to be beneficial and the SBP and DBP, as well as the HR returned to normal values. In IV – experimental group S/V revealed preventive action regarding hemodynamic changes during development of AH by decreasing values of SBP ( -50 ± 11,8 mmHg, p<0,001), DBP (-16 ± 6,0 mmHg, p<0,001), and HB (­- 67 ± 15,6 beat/min, p<0,001). In hypertensive rats, the level of inflammatory markers increased significantly, namely IL-1 was 8.6 pg/ml and TNF-alpha was 46.8 pg/ml. Both values returned to normal range after the use of S/V in experimental groups III and IV. In a group of rats with DOCA-induced hypertension, melatonin levels were significantly decreased compared to the control group (-6 pg/ml) and increased again after prevention and treatment of hypertension with S/V. Respectively, an improvement in the disturbed circadian rhythm of hemodynamic parameters was revealed in the same experimental groups of animals. Contrary to melatonin, levels of angiotensin II were increased in hypertensive rats and decreased after blood pressure normalization with S/V combination.

We hypothesize that during arterial hypertension, elevated circulating angiotensin II crosses the blood-brain barrier and acts on the melatonin-synthesizing enzyme tryptophan hydroxylase causing its downregulation, which is followed by a decrease in melatonin levels. This in turn causes increase in the inflammatory mediators IL1 and TNF. Based on the data obtained as a result of our study, we can conclude that the S/V combination has a multiple mechanism of action that is likely to have significant positive effects on the long-term outcomes of hypertension and patient survival.


Download data is not yet available.

Author Biographies

DAVIT GOLOSHVILI, Tbilisi State Medical University

Department of Medical Pharmacology

MAIA OKUJAVA, Tbilisi State Medical University

Department of Medical Pharmacology

GIA BURJANADZE, Tbilisi State Medical University

Department of Biochemistry

MAKRINE MIRZIASHVILI, Tbilisi State Medical University

Department of Medical Pharmacology

MANANA GHONGHADZE, Tbilisi State Medical University

Department of Medical Pharmacology

NIKOLOZ GONGADZE, Tbilisi State Medical University

Department of Medical Pharmacology


Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018 Jun 7;39(22):2063-2069. doi: 10.1093/eurheartj/ehy128. PMID: 29584915.

Martín-Fernández J, Alonso-Safont T, Polentinos-Castro E, et al. Impact of hypertension diagnosis on morbidity and mortality: a retrospective cohort study in primary care. BMC Prim Care. 2023 Mar 23;24(1):79. doi: 10.1186/s12875-023-02036-2.

Shihab HM, Meoni LA, Chu AY, Wang NY, Ford DE, Liang KY, Gallo JJ, Klag MJ. Body mass index and risk of incident hypertension over the life course: The Johns Hopkins Precursors Study. Circulation. 2012 Dec 18;126(25):2983-9. doi: 10.1161/CIRCULATIONAHA.112.117333. Epub 2012 Nov 14. PMID: 23151344; PMCID: PMC3743236.

Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8.

Bavishi C, Bangalore S, Messerli FH. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction? Prog Cardiovasc Dis. 2016 Nov-Dec;59(3):253-261. doi: 10.1016/j.pcad.2016.10.002. Epub 2016 Oct 21. PMID: 27777044.

Nicolas D, Kerndt CC, Reed M. Sacubitril-Valsartan. 2022 May 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 29939681.

Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8.

Angeli F, Reboldi G, Trapasso M, Gentile G, Pinzagli MG, Aita A, Verdecchia P. European and US guidelines for arterial hypertension: similarities and differences. Eur J Intern Med. 2019 May; 63:3-8. doi: 10.1016/j.ejim.2019.01.016. Epub 2019 Feb 4. PMID: 30732939.

Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J of Molecular Medicine. 2001;79(2):76–102.

Campos LA, Bader M, Baltatu OC. Brain renin-angiotensin system in hypertension, cardiac hypertrophy, and heart failure. Frontiers in Physiology. 2011;2, artile 115

Baltatu OC, Campos LA, Bader M. Local renin-angiotensin system and the brain: a continuous quest for knowledge. Peptides. 2011;32(5):1083–1086.

Du AX, Westerhout CM, McAlister FA, et al. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. J Cardiovasc Pharmacol. 2019 Mar;73(3):149-154. doi: 10.1097/FJC.0000000000000643.

von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013 Apr;27(2):171-9. doi: 10.1007/s10557-012-6424-y. PMID: 23224653

Nicolas D, Kerndt CC, Reed M. Sacubitril-Valsartan. [Updated 2022 May 26]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507904/

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in: Circulation. 2022 May 3;145(18):e1033. Erratum in: Circulation. 2022 Sep 27;146(13):e185. Erratum in: Circulation. 2023 Apr 4;147(14):e674.

In brief: Sacubitril/valsartan (Entresto) expanded indication. Med Lett Drugs Ther. 2021 May 3;63(1623):65.

Pruijm M, Vollenweider P, Mooser V, et al. Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus Study. J Hum Hypertens. 2013 Mar;27(3):169-75. doi: 10.1038/jhh.2012.12. Epub 2012 Apr 12. PMID: 22495106.

Aydin C, Alpsoy Ş, Akyüz A, et al. Could the systemic immune-inflammation index be a predictor to estimate cerebrovascular events in hypertensive patients? Blood Press Monit. 2022 Feb 1;27(1):33-38. doi: 10.1097/MBP.0000000000000560.

Yihui C, Yanfeng G. Inflammatory markers in patients with hypertension. Br J Hosp Med (Lond). 2023 May 2;84(5):1-8. doi: 10.12968/hmed.2022.0531. Epub 2023 May 22. PMID: 37235676.

Gupta V, Sachdeva S, Khan AS, Haque SF. Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi J Kidney Dis Transpl. 2011 Jan;22(1):97-103. PMID: 21196621.

Tenório MB, Ferreira RC, Moura FA, Bueno NB, de Oliveira ACM, Goulart MOF. Cross-Talk between Oxidative Stress and Inflammation in Preeclampsia. Oxid Med Cell Longev. 2019 Nov 4;2019:8238727. doi: 10.1155/2019/8238727. PMID: 31781353; PMCID: PMC6875353.

Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace K, LaMarca B. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond). 2016 Mar;130(6):409-19. doi: 10.1042/CS20150702. PMID: 26846579; PMCID: PMC5484393.

Winklewski PJ, Radkowski M, Wszedybyl-Winklewska M, Demkow U. Brain inflammation and hypertension: the chicken or the egg? J Neuroinflammation. 2015 May 3;12:85. doi: 10.1186/s12974-015-0306-8.

Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. Journal of Physiology Paris. 2011;105(4-6):170–182.

Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. The Scientific World Journal. 2012;2012:18 pages.640389

Carpentieri A, Díaz de Barboza G, Areco V, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacological Research. 2012;65(4):437–444.

Zefferino R, Di Gioia S, Conese M. Molecular links between endocrine, nervous and immune system during chronic stress. Brain Behav. 2021 Feb;11(2):e01960. doi: 10.1002/brb3.1960. Epub 2020 Dec 8. PMID: 33295155; PMCID: PMC7882157.

Ohkubo T., Hozawa A., Yamaguchi J., et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J. Hypertens. 2002;20:2183–2189. doi: 10.1097/00004872-200211000-00017.

Virag J.A., Lust R.M. Circadian influences on myocardial infarction. Front. Physiol. 2014;5:422. doi: 10.3389/fphys.2014.00422.

Yagi S, Sata M. [Renin-angiotensin-aldosterone inhibitors for treatment of hypertension with abnormal circadian rhythm of blood pressure]. Nihon Rinsho. 2014 Aug;72(8):1466-71. Japanese. PMID: 25167754.

Campos LA, Couto AS, Iliescu R, et al. Differential regulation of central vasopressin receptors in transgenic rats with low brain angiotensinogen. Regulatory Peptides. 2004;119(3):177–182.

Baltatu O, Nishimura H, Hoffmann S, et al. High levels of human chymase expression in the pineal and pituitary glands. Brain Research. 1997;752(1-2):269–278.

Baltatu O, Lippoldt A, Hansson A, Ganten D, Bader M. Local renin-angiotensin system in the pineal gland. Molecular Brain Research. 1998;54(2):237–242.

Schieffer B, Schieffer E, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000 Mar 28;101(12):1372-8. doi: 10.1161/01.cir.101.12.1372. PMID: 10736279.

Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1623-9. doi: 10.1161/01.atv.19.7.1623. PMID: 10397679.

Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010 Jul;2(7):247-57. doi: 10.1002/emmm.201000080. PMID: 20597104

Anderson GH Jr, Howland T, Domschek R, Streeten DH. Effect of sodium balance and calcium channel-blocking drugs on plasma aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension. J Clin Endocrinol Metab. 1986 Nov;63(5):1126-35. doi: 10.1210/jcem-63-5-1126.

Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960. doi: 10.1155/2014/406960. Epub 2014 Jul 20. PMID: 25136585; PMCID: PMC4124649.

Matsumori A. Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. Eur Cardiol. 2023 Jun 7;18:e40. doi: 10.15420/ecr.2023.10. PMID: 37456770;

Ruiz-Ortega M, Lorenzo O, Rupérez M, König S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res. 2000 Jun 23;86(12):1266-72. doi: 10.1161/01.res.86.12.1266. PMID: 10864918.

Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, Poupot R, Cantagrel A. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013 Apr;52(4):590-8. doi: 10.1093/rheumatology/kes304. Epub 2012 Nov 30. PMID: 23204551.

Krishnan SM, Ling YH, Huuskes BM, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019 Mar 15;115(4):776-787. doi: 10.1093/cvr/cvy252. PMID: 30357309; PMCID: PMC6432065.

Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010 Feb;10(2):89-102. doi: 10.1038/nri2691. Epub 2010 Jan 18. PMID: 20081871.

Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol. 1988 Feb;106(2):311-8. doi: 10.1083/jcb.106.2.311. PMID: 2828381; PMCID: PMC2114989.

Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003 Sep;3(9):745-56. doi: 10.1038/nri1184. PMID: 12949498.

Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets. Front Immunol. 2023 Jan 10;13:1098725. doi: 10.3389/fimmu.2022.1098725. PMID: 36703963; PMCID: PMC9871625.

Guerrero, J. M. , & Reiter, R. J. (2002). Melatonin‐immune system relationships. Current Topics in Medicinal Chemistry, 2(2), 167–179. 10.2174/1568026023394335.

Hardeland, R., Burkhardt, S., Antolin, I., Fuhrberg, B., & Coto‐Montes, A. (1999). Melatonin and 5‐methoxytryptamine in the bioluminescent dinoflagellate Gonyaulax polyedra. Restoration of the circadian glow peak after suppression of indoleamine biosynthesis or oxidative stress. Advances in Experimental Medicine and Biology, 460, 387–390.

Withyachumnarnkul, B., Nonaka, K. O., Santana, C., Attia, A. M., & Reiter, R. J. (1990). Interferon‐gamma modulates melatonin production in rat pineal glands in organ culture. Journal of Interferon Research, 10(4), 403–411. 10.1089/jir.1990.10.403.

da Silveira Cruz‐Machado, S., Pinato, L., Tamura, E. K., Carvalho‐Sousa, C. E., & Markus, R. P. (2012). Glia‐pinealocyte network: The paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One, 7(7), e40142 10.1371/journal.pone.0040142.

Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin’s role in antiaging mechanisms. J Pineal Res. 2013; 55:325–56. 10.1111/jpi.12090.

Rezapoor S, Shirazi A, Abbasi S, et al. Modulation of Radiation-induced Base Excision Repair Pathway Gene Expression by Melatonin. J Med Phys. 2017; 42:245–50. 10.4103/jmp.JMP_9_17

Hermida RC, Crespo JJ, Otero A, Domínguez-Sardiña M, et al. Hygia Project Investigators. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J. 2018 Dec 14;39(47):4159-4171. doi: 10.1093/eurheartj/ehy475. PMID: 30107515.

Huang CC, Chiou CH, Liu SC, Hu SL, Su CM, Tsai CH, Tang CH. Melatonin attenuates TNF-α and IL-1β expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. J Pineal Res. 2019 Apr;66(3):e12560. doi: 10.1111/jpi.12560.




How to Cite





Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.